Cargando…
Development and Validation of a New LC-MS/MS Bioanalytical Method for the Simultaneous Determination of Levodopa, Levodopa Methyl Ester, and Carbidopa in Human Plasma Samples
Levodopa (L-DOPA) treatment, combined with the administration of dopa-decarboxylase inhibitors (DDCIs), is still the most effective symptomatic treatment of Parkinson’s disease (PD). Although its efficacy in the early stage of the disease has been confirmed, its complex pharmacokinetics (PK) increas...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254897/ https://www.ncbi.nlm.nih.gov/pubmed/37298741 http://dx.doi.org/10.3390/molecules28114264 |
_version_ | 1785056750296104960 |
---|---|
author | Molteni, Linda Charlier, Bruno Izzo, Viviana Coglianese, Albino Conti, Valeria Eleopra, Roberto Cilia, Roberto Capelli, Chiara D’Urso, Annachiara de Grazia, Ugo |
author_facet | Molteni, Linda Charlier, Bruno Izzo, Viviana Coglianese, Albino Conti, Valeria Eleopra, Roberto Cilia, Roberto Capelli, Chiara D’Urso, Annachiara de Grazia, Ugo |
author_sort | Molteni, Linda |
collection | PubMed |
description | Levodopa (L-DOPA) treatment, combined with the administration of dopa-decarboxylase inhibitors (DDCIs), is still the most effective symptomatic treatment of Parkinson’s disease (PD). Although its efficacy in the early stage of the disease has been confirmed, its complex pharmacokinetics (PK) increases the variability of the intra-individual motor response, thus amplifying the risk of motor/non-motor fluctuations and dyskinesia. Moreover, it has been demonstrated that L-DOPA PK is strongly influenced by several clinical, therapeutic, and lifestyle variables (e.g., dietary proteins). L-DOPA therapeutic monitoring is therefore crucial to provide personalized therapy, hence improving drug efficacy and safety. To this aim, we have developed and validated an ultra-high performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) method to quantify L-DOPA, levodopa methyl ester (LDME), and the DDCI carbidopa in human plasma. The compounds were extracted by protein precipitation and samples were analyzed with a triple quadrupole mass spectrometer. The method showed good selectivity and specificity for all compounds. No carryover was observed, and dilution integrity was demonstrated. No matrix effect could be retrieved; intra-day and inter-day precision and accuracy values met the acceptance criteria. Reinjection reproducibility was assessed. The described method was successfully applied to a 45-year-old male patient to compare the pharmacokinetic behavior of an L-DOPA-based medical treatment involving commercially available Mucuna pruriens extracts and an LDME/carbidopa (100/25 mg) formulation. |
format | Online Article Text |
id | pubmed-10254897 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102548972023-06-10 Development and Validation of a New LC-MS/MS Bioanalytical Method for the Simultaneous Determination of Levodopa, Levodopa Methyl Ester, and Carbidopa in Human Plasma Samples Molteni, Linda Charlier, Bruno Izzo, Viviana Coglianese, Albino Conti, Valeria Eleopra, Roberto Cilia, Roberto Capelli, Chiara D’Urso, Annachiara de Grazia, Ugo Molecules Article Levodopa (L-DOPA) treatment, combined with the administration of dopa-decarboxylase inhibitors (DDCIs), is still the most effective symptomatic treatment of Parkinson’s disease (PD). Although its efficacy in the early stage of the disease has been confirmed, its complex pharmacokinetics (PK) increases the variability of the intra-individual motor response, thus amplifying the risk of motor/non-motor fluctuations and dyskinesia. Moreover, it has been demonstrated that L-DOPA PK is strongly influenced by several clinical, therapeutic, and lifestyle variables (e.g., dietary proteins). L-DOPA therapeutic monitoring is therefore crucial to provide personalized therapy, hence improving drug efficacy and safety. To this aim, we have developed and validated an ultra-high performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) method to quantify L-DOPA, levodopa methyl ester (LDME), and the DDCI carbidopa in human plasma. The compounds were extracted by protein precipitation and samples were analyzed with a triple quadrupole mass spectrometer. The method showed good selectivity and specificity for all compounds. No carryover was observed, and dilution integrity was demonstrated. No matrix effect could be retrieved; intra-day and inter-day precision and accuracy values met the acceptance criteria. Reinjection reproducibility was assessed. The described method was successfully applied to a 45-year-old male patient to compare the pharmacokinetic behavior of an L-DOPA-based medical treatment involving commercially available Mucuna pruriens extracts and an LDME/carbidopa (100/25 mg) formulation. MDPI 2023-05-23 /pmc/articles/PMC10254897/ /pubmed/37298741 http://dx.doi.org/10.3390/molecules28114264 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Molteni, Linda Charlier, Bruno Izzo, Viviana Coglianese, Albino Conti, Valeria Eleopra, Roberto Cilia, Roberto Capelli, Chiara D’Urso, Annachiara de Grazia, Ugo Development and Validation of a New LC-MS/MS Bioanalytical Method for the Simultaneous Determination of Levodopa, Levodopa Methyl Ester, and Carbidopa in Human Plasma Samples |
title | Development and Validation of a New LC-MS/MS Bioanalytical Method for the Simultaneous Determination of Levodopa, Levodopa Methyl Ester, and Carbidopa in Human Plasma Samples |
title_full | Development and Validation of a New LC-MS/MS Bioanalytical Method for the Simultaneous Determination of Levodopa, Levodopa Methyl Ester, and Carbidopa in Human Plasma Samples |
title_fullStr | Development and Validation of a New LC-MS/MS Bioanalytical Method for the Simultaneous Determination of Levodopa, Levodopa Methyl Ester, and Carbidopa in Human Plasma Samples |
title_full_unstemmed | Development and Validation of a New LC-MS/MS Bioanalytical Method for the Simultaneous Determination of Levodopa, Levodopa Methyl Ester, and Carbidopa in Human Plasma Samples |
title_short | Development and Validation of a New LC-MS/MS Bioanalytical Method for the Simultaneous Determination of Levodopa, Levodopa Methyl Ester, and Carbidopa in Human Plasma Samples |
title_sort | development and validation of a new lc-ms/ms bioanalytical method for the simultaneous determination of levodopa, levodopa methyl ester, and carbidopa in human plasma samples |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254897/ https://www.ncbi.nlm.nih.gov/pubmed/37298741 http://dx.doi.org/10.3390/molecules28114264 |
work_keys_str_mv | AT moltenilinda developmentandvalidationofanewlcmsmsbioanalyticalmethodforthesimultaneousdeterminationoflevodopalevodopamethylesterandcarbidopainhumanplasmasamples AT charlierbruno developmentandvalidationofanewlcmsmsbioanalyticalmethodforthesimultaneousdeterminationoflevodopalevodopamethylesterandcarbidopainhumanplasmasamples AT izzoviviana developmentandvalidationofanewlcmsmsbioanalyticalmethodforthesimultaneousdeterminationoflevodopalevodopamethylesterandcarbidopainhumanplasmasamples AT coglianesealbino developmentandvalidationofanewlcmsmsbioanalyticalmethodforthesimultaneousdeterminationoflevodopalevodopamethylesterandcarbidopainhumanplasmasamples AT contivaleria developmentandvalidationofanewlcmsmsbioanalyticalmethodforthesimultaneousdeterminationoflevodopalevodopamethylesterandcarbidopainhumanplasmasamples AT eleopraroberto developmentandvalidationofanewlcmsmsbioanalyticalmethodforthesimultaneousdeterminationoflevodopalevodopamethylesterandcarbidopainhumanplasmasamples AT ciliaroberto developmentandvalidationofanewlcmsmsbioanalyticalmethodforthesimultaneousdeterminationoflevodopalevodopamethylesterandcarbidopainhumanplasmasamples AT capellichiara developmentandvalidationofanewlcmsmsbioanalyticalmethodforthesimultaneousdeterminationoflevodopalevodopamethylesterandcarbidopainhumanplasmasamples AT dursoannachiara developmentandvalidationofanewlcmsmsbioanalyticalmethodforthesimultaneousdeterminationoflevodopalevodopamethylesterandcarbidopainhumanplasmasamples AT degraziaugo developmentandvalidationofanewlcmsmsbioanalyticalmethodforthesimultaneousdeterminationoflevodopalevodopamethylesterandcarbidopainhumanplasmasamples |